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Background: Exacerbations of airway disease are eosinophilic, neutrophilic, both or
neither, and this determines the treatment needed. We examined changes in the cellular
nature of airway inflammation between consecutive exacerbations and their predictors in
individual patients.
Methods: In a retrospective survey of 1786 consecutive sputum cell counts from 1139
patients with airway disease, we identified 79 patients with two or more exacerbations at
an interval ofX6 weeks. The patients were divided into those who demonstrated a change
in the type of airway inflammation and those who did not.
Results: There were 186 exacerbations of airway disease over 22 months. The cellular
nature of inflammation was eosinophilic in 43%, neutrophilic in 40%, combined eosinophilic
and neutrophilic in 5% and unclassified in 12%. A change in the type of airway inflammation
was seen in 38 patients (48%). Patients, whose previous exacerbation was eosinophilic or
neutrophilic were twice or nearly three times more likely, respectively, to have a
subsequent exacerbation of the same type. There was no significant difference in the time
to the second exacerbation or the inflammatory type of the second exacerbation in
relation to the first exacerbation, irrespective of the cellular nature of the first
exacerbation.Elsevier Ltd. All rights reserved.
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L. D’silva et al.2218Conclusions: Quantitative sputum cell counts during successive exacerbations identify
that they are commonly of different type, reflecting different causes and the need for
different treatment. Their use, when available, helps to optimize therapy.
& 2007 Elsevier Ltd. All rights reserved.Background
Exacerbations of airway disease are a major cause of
morbidity, mortality and economic burden to the patient
and society.1,2 Exacerbations are usually associated with
worsening of airway inflammation which, as identified by
quantitative sputum cell counts, can be neutrophilic,
eosinophilic, combined eosinophilic and neutrophilic or
neither.3 These are a result of different causes such as
infections,4,5 allergens,6 occupational chemicals7 or too
little corticosteroid treatment.8,9 As these causes are
common, the type of exacerbation is likely to vary from
time to time. This has not been examined in individual
subjects over a period of time.Methods
In January 2004, a database of clinical sputum cell counts
was established at the Firestone Institute for Respiratory
Health, a tertiary care centre. Over the first 22 months,
1786 measurements were performed in 1139 patients. In a
retrospective survey of these results, we identified 79
patients, aged 17–85 years, who had two or more measure-
ments during exacerbations of physician diagnosed asthma,
chronic airflow limitation (COPD), bronchiectasis or chronic
cough at intervals of X6 weeks (we arbitrarily defined the
duration of one exacerbation as up to 6 weeks). We
examined how often the cellular nature of airway inflam-
mation was the same and how often was it different during
successive exacerbations in individual patients. The study
was approved by the hospital Research Ethics Board.
Exacerbations were regarded as synonymous with the loss
of symptomatic control. The treating clinicians were blinded
to the results of the induced sputum at the time of an
exacerbation.
An exacerbation was defined by an increase in cough,
dyspnoea, sputum volume or purulence or fall in FEV1 by at
least 20% that in the opinion of the physician required an
adjustment to therapy.3 A ‘‘neutrophilic’’ exacerbation was
defined as that with a total cell count ofX12 million cells/g
of sputum selected from the expectorate and proportion of
neutrophils X80%.10 An ‘‘eosinophilic’’ exacerbation, which
is not usually associated with a raised total cell count, was
defined as a percentage of sputum eosinophils X3%.3 A
combined ‘‘eosinophilic and neutrophilic’’ exacerbation was
defined as total cell count ofX12 million cells/g of sputum,
neutrophils X80% and eosinophils X3%. An ‘‘unclassified
(neither eosinophilic nor neutrophilic)’’ type of exacerba-
tion included patients who had symptoms of an exacerbation
with neutrophilso80% and eosinophilso3%. This group also
included those exacerbations with an isolated raised totalcell count (X12 million cells/g of sputum). A diagnosis of
asthma was based on information provided by the referring
physician, which included a compatible clinical history with
evidence of reversible airflow limitation, airway hyper-
responsiveness or both. Chronic airflow limitation included
patients who were diagnosed with COPD, as indicated by a
post-bronchodilator forced expiratory volume in 1 s (FEV1)/
slow vital capacity (SVC) of o70%.11 Sputum induction and
examination for total and differential cell counts were
performed by the methods used by Pizzichini et al.12
Descriptive statistics were used to summarize the types of
exacerbations. The time from one exacerbation to the next
was analyzed according to a recurrent event competing risk
analysis.13 Strata were defined based on the most recent
type of exacerbation. Cox regression models were also fitted
for the time of the second and subsequent exacerbations by
type using the type of the most recent exacerbation as a
categorical predictor variable. These predictor variables
provided estimates of relative risk indicating the extent to
which the risk of exacerbations of a particular type changed
as a function of the most recent exacerbations, and hence
the extent to which patients tended to have exacerbations
of the same type. In addition to the relative risk, two-
sided 95% confidence intervals were obtained along with
formal tests of significance with alpha ¼ 0.05. (SPSS
Graduate PackTM 13.0 for Windows, Chicago, IL, USA, 2005
and S-PLUS 7, MathSoft, Inc., Cambridge, MA, USA, 2005).
Results
Seventy nine patients had at least two exacerbations, 18
had three, 7 had four and 3 had five exacerbations over 22
months. The exacerbations were eosinophilic in 43%,
neutrophilic in 40%, combined in 5% and unclassified in
12%. In patients with asthma, there were 65 eosinophilic, 27
neutrophilic, 4 combined and 11 unclassified exacerbations;
however, in patients with COPD, there were 13 eosinophilic,
32 neutrophilic, 5 combined eosinophilic and neutrophilic
and 6 unclassified exacerbations.
The pattern of airway inflammation during consecutive
exacerbations was different in 38 (48%) patients and the
same in the remaining 41 (52%) patients. Patients whose
previous exacerbation was eosinophilic or neutrophilic,
were twice (RR ¼ 2.217, 95% CI 1.105, 4.447, p ¼ 0.025)
or nearly three times (RR ¼ 2.903, 95% CI 1.433, 5.883,
p ¼ 0.003) more likely to have a subsequent eosinophilic or
neutrophilic exacerbation, respectively (Fig. 1A). There was
no significant difference in the time to the second
exacerbation or the inflammatory type of the second
exacerbation in relation to the first exacerbation, irrespec-
tive of the cellular nature of the first exacerbation (Fig. 1B).
The type of bronchitis in patients with asthma changed in 24
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Figure 1 (A) Panel A: The proportion of patients expected to have a subsequent eosinophilic exacerbation is higher if the previous
exacerbation is eosinophilic, compared to a neutrophilic exacerbation (p ¼ 0.025). Panel B: The proportion of patients expected to
have a subsequent neutrophilic exacerbation is higher if the previous exacerbation is neutrophilic, compared to an eosinophilic
exacerbation (p ¼ 0.003). (B) There was no significant difference in the time to the second exacerbation or the inflammatory type of
the second exacerbation in relation to the first exacerbation, irrespective of the cellular nature of the first exacerbation.
Changing pattern of sputum cell counts during successive exacerbations of airway disease 2219and was the same in 20 and in those with COPD changed in
12 and was the same in 13. All 4 patients with bronchiectasis
had the same exacerbations, whereas in patients with
chronic cough the type of inflammation changed in 2 and
was the same in 4.Conclusion
This retrospective study demonstrates that in roughly 50% of
patients with exacerbations of airway disease, the nature of
airway inflammation can change between consecutive
exacerbations. This observation is relevant to clinical
practice, since the treatment of neutrophilic and eosino-
philic exacerbations differs according to the cause. They
indicate that a ‘‘one size fits all’’ approach for example, by
recommending combination therapy of inhaled corticoster-
oids and long acting bronchodilators for all exacerbations is
not necessarily appropriate.14 Since the type of airway
inflammation during an exacerbation is determined by the
cause which cannot be guessed based on clinical features,15quantitative measurements of airway inflammation may be
needed to guide the most appropriate treatment.
While it is known from cross-sectional studies that asthma
exacerbations can be associated with eosinophilic, non-
eosinophilic, combined eosinophilic and neutrophilic or
pauci-inflammatory phenotypes16–19 and while sputum eosi-
nophils or neutrophils have been shown to be significantly
increased during COPD exacerbations,20 this is the first time
that the nature of airway inflammation has been examined
during consecutive exacerbations. The result illustrates a
limitation of cross-sectional studies that categorise patients
into ‘inflammatory phenotypes’.21
The strengths of this study are the excellent reliability,
validity and responsiveness of sputum cell counts.22 The
weakness is the retrospective design. We did not consider
sputum cell counts re-examined within 6 weeks, since the
symptomatic and physiologic recovery from an exacerbation
is generally reported as 2–6 weeks.5,23 Although we did not
examine the predictive effect of treatment intervention on
the pattern of airway inflammation during subsequent
exacerbations, we found that there was no significant
difference between the total dose of inhaled corticosteroids
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L. D’silva et al.2220(median 2000 vs. 1600mcg) and total dose of prednisone
(median 0 vs. 0mg) during the study period in those patients
who showed a changing or same recurring type of exacer-
bation.
Further prospective studies are needed in which the
components of disease, the treatment being taken prior to
the exacerbation and the type and cause of each exacer-
bation are critically examined, all of which are important to
optimize treatment. Sputum cell counts have now shown to
be useful in the management of patients with moderate and
severe asthma3 and COPD.24 These results further emphasize
the need for sputum measurements in patients with
recurring exacerbations.
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